A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Status: Recruiting
Location: See all (22) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 75
Healthy Volunteers: f
View:
• Diagnosis of HS for at least 6 months before screening visit.
• Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.
• Total estimated treatment BSA \> 20% at screening and baseline.
• Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
• Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
• Further inclusion criteria apply.
Locations
United States
Arizona
Saguaro Dermatology
NOT_YET_RECRUITING
Phoenix
California
First Oc Dermatology
RECRUITING
Fountain Valley
Amicis Research Center Valencia
RECRUITING
Northridge
Children'S Hospital of Orange County
NOT_YET_RECRUITING
Orange
Clinical Trials Research Institute
RECRUITING
Thousand Oaks
Colorado
Clarity Dermatology
NOT_YET_RECRUITING
Castle Rock
Florida
International Clinical Research Tennessee Llc
RECRUITING
Sanford
Lenus Research Medical Group, Llc
RECRUITING
Sweetwater
Trueblue Clinical Research
RECRUITING
Tampa
Georgia
Lane Dermatology and Dermatologic Surgery
RECRUITING
Columbus
Indiana
Options Research Group, Llc
NOT_YET_RECRUITING
West Lafayette
Kentucky
Equity Medical, Llc
RECRUITING
Bowling Green
Louisiana
Delricht Research
RECRUITING
Baton Rouge
Michigan
Revival Research Institute, Llc Troy
RECRUITING
Troy
Missouri
Red River Research Partners
RECRUITING
Bolivar
North Dakota
Red River Research Partners
RECRUITING
Fargo
New York
Dr Bobby Buka, Md Greenwich Village
NOT_YET_RECRUITING
New York
Equity Medical, Llc
RECRUITING
New York
Ohio
Centricity Research Columbus
RECRUITING
Columbus
Oklahoma
Unity Clinical Research
RECRUITING
Oklahoma City
Pennsylvania
Paddington Testing Co Inc
RECRUITING
Philadelphia
Texas
Dermresearch, Inc.
WITHDRAWN
Austin
Contact Information
Primary
Incyte Corporation Call Center (US)
medinfo@incyte.com
1.855.463.3463
Backup
Incyte Corporation Call Center (ex-US)
eumedinfo@incyte.com
+800 00027423
Time Frame
Start Date: 2025-11-03
Estimated Completion Date: 2026-12-09
Participants
Target number of participants: 24
Treatments
Experimental: Ruxolitinib 1.5 % Cream
Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.
Related Therapeutic Areas
Sponsors
Leads: Incyte Corporation